+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 4
Age: 18Years +
All Genders
ID07094048

Study of Immunoglobulin Support Levels in Adults with Multiple Myeloma Receiving BCMA-Directed T Cell Engager Therapy to Reduce Severe Infections

Led by CHU de Quebec-Universite Laval · Updated on 2026-07-22

80

Participants Needed

2

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are investigating the use of bispecific antibody therapies that target BCMA B-cell maturation antigen for patients with multiple myeloma, a serious blood cancer. These therapies are currently used mainly for patients with refractory multiple myeloma but are also being tested earlier in treatment. Because these treatments can cause deeper immunosuppression, patients face a higher risk of infections, making infection prevention a key concern. However, the best strategies for preventing infections in this group are not yet clear. The study compares two approaches to giving immunoglobulin Ig support to patients receiving BCMA-directed T-cell engager therapy. Patients with relapsed or refractory multiple myeloma who have a history of recurrent or severe infections or low IgG levels will receive Ig support either intravenously or subcutaneously. The study aims to determine if targeting a lower trough IgG level of 4 to 6 gL is as effective at reducing severe infections as the standard target level of 8 to 10 gL. Some patients without infection history or low IgG may not initially receive Ig support but may switch groups if needed during follow-up. Participants will be closely monitored for infections and IgG levels from enrollment through 12 months after randomization. The main measurement is the rate of severe infections within the first 3 months. Researchers will also track minor and all infections over a year. Regular assessments will include blood tests to measure IgG levels and infection evaluations. This randomized, unblinded study aims to provide guidance on optimal IgG targets to better protect multiple myeloma patients receiving these novel therapies. The trial runs from early 2026 through late 2029.

CONDITIONS

Brief Title

Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell Engager

Research Team

P

Philippe Nadeau, PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here